



Level 2, 517 Flinders Lane
Melbourne Australia 3000

ACN: 123 055 363
website: www.patrys.com

Media Release

Melbourne, 13 July 2007

Successful Listing for Human Antibody Therapeutics Company

Natural human antibody company Patrys Limited ("Patrys") (ASX Code: PAB) listed on the Australian Stock Exchange ("ASX") at 11am today at \$0.64, a premium of 60 per cent to its issue price of A\$0.40.

Patrys operates in the rapidly growing and successful field of antibody therapeutics, commercialising its proprietary platform technologies for the capture, production and development of natural human antibodies as therapies for cancer and many other diseases.

Patrys Chief Executive Officer Daniel Devine commented: "We are delighted with the broad institutional and retail investor support for the Company. Now that we've successfully listed, we look forward to rapidly progressing the development and commercialisation of our lead antibodies".

"The Company has an exciting path forward, having a deep pipeline of anti-cancer natural human antibodies. We're progressing two of our lead antibodies towards Phase I/IIa human clinical trials and are working in close collaboration with larger pharmaceutical companies to develop a number of additional natural human antibodies from our pipeline."

Patrys raised A\$25,000,000 through the public offer which was fully underwritten by Lodge Corporate Services Pty Limited.

Ends –

For investor & media enquiries please contact:

Jo May / John Dowell

Alitum Partnership

T: +61 3 9200-7066

M: +61 412 537-005 / +61 404 476-499